DSG4: A Non-Coding RNA Molecule with Potential as A Drug Target and Biomarker

Target Name: DSG4

NCBI ID: G147409

DSG4

DSG4: A Non-Coding RNA Molecule with Potential as A Drug Target and Biomarker

DSG4 (CDH family member 13) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and subcellular localization have made it an attractive target for drug developers due to its potential to modulate gene expression and contribute to the development of various diseases.

DSG4 is a part of the CDH family, which is a group of non-coding RNAs that have been shown to play a role in the development and progression of various diseases, including cancer. The CDH family members are characterized by the presence of a specific stem-loop region, which is a common feature in many RNA molecules. This region is known as the N-terminal Baojiatou, and it is the region that gives the CDH molecules their unique structure and function.

DSG4 is a small molecule that has been shown to interact with several proteins, including the transcription factor E2F1, which is known to play a role in the regulation of gene expression. This interaction between DSG4 and E2F1 has been shown to promote the translation of DSG4 RNA into proteins, which may contribute to its potential as a drug target.

DSG4 has also been shown to interact with the protein PDGF-BB, which is a key signaling molecule in the development and progression of cancer. This interaction between DSG4 and PDGF-BB has been shown to promote the growth and survival of cancer cells, which may contribute to its potential as a biomarker for cancer.

In addition to its potential as a drug target and biomarker, DSG4 has also been shown to play a role in the regulation of cellular processes, including cell division, apoptosis, and inflammation. This suggests that DSG4 may be a useful tool for the development of new therapeutic approaches for a variety of diseases.

DSG4 has also been shown to be expressed in a variety of tissues and cells, including the brain, liver, and cancer cells. This suggests that it may be a potential drug target that can be targeted by small molecules, which could be used to treat a wide range of diseases.

In conclusion, DSG4 is a promising drug target and biomarker that has the potential to contribute to the development of new therapeutic approaches for a variety of diseases. Its unique structure and subcellular localization, as well as its interaction with several proteins, including the transcription factor E2F1 and the protein PDGF-BB, suggest that it may be a valuable tool for the development of new therapeutic approaches for the treatment of cancer and other diseases. Further research is needed to fully understand the potential of DSG4 as a drug target and biomarker.

Protein Name: Desmoglein 4

Functions: Component of intercellular desmosome junctions. Involved in the interaction of plaque proteins and intermediate filaments mediating cell-cell adhesion. Coordinates the transition from proliferation to differentiation in hair follicle keratinocytes (By similarity)

The "DSG4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DSG4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets